The stock of TG Therapeutics Inc (NASDAQ:TGTX) is a huge mover today! About 354,882 shares traded hands or 17.13% up from the average. TG Therapeutics Inc (NASDAQ:TGTX) has risen 8.49% since March 8, 2016 and is uptrending. It has underperformed by 0.83% the S&P500.
The move comes after 7 months negative chart setup for the $518.08M company. It was reported on Oct, 11 by Barchart.com. We have $8.28 PT which if reached, will make NASDAQ:TGTX worth $31.08M less.
Analysts await TG Therapeutics Inc (NASDAQ:TGTX) to report earnings on November, 14. They expect $-0.32 EPS, down 14.29% or $0.04 from last year’s $-0.28 per share. After $-0.33 actual EPS reported by TG Therapeutics Inc for the previous quarter, Wall Street now forecasts -3.03% EPS growth.
TG Therapeutics Inc (NASDAQ:TGTX) Ratings Coverage
Out of 6 analysts covering TG Therapeutics (NASDAQ:TGTX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TG Therapeutics has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The company was initiated on Friday, May 27 by SunTrust. The stock of TG Therapeutics Inc (NASDAQ:TGTX) has “Outperform” rating given on Tuesday, December 1 by FBR Capital. The firm earned “Strong Buy” rating on Wednesday, September 9 by Raymond James. The stock of TG Therapeutics Inc (NASDAQ:TGTX) earned “Buy” rating by Brean Capital on Thursday, October 6. The stock of TG Therapeutics Inc (NASDAQ:TGTX) has “Buy” rating given on Wednesday, August 12 by H.C. Wainwright. The stock of TG Therapeutics Inc (NASDAQ:TGTX) has “Hold” rating given on Wednesday, August 12 by Zacks. As per Friday, May 27, the company rating was initiated by Suntrust Robinson.
According to Zacks Investment Research, “TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.”
Insitutional Activity: The institutional sentiment increased to 1.54 in 2016 Q2. Its up 0.09, from 1.45 in 2016Q1. The ratio improved, as 10 funds sold all TG Therapeutics Inc shares owned while 18 reduced positions. 14 funds bought stakes while 29 increased positions. They now own 29.49 million shares or 0.54% more from 29.33 million shares in 2016Q1.
Moreover, Numeric Invsts Ltd Liability Com has 0% invested in TG Therapeutics Inc (NASDAQ:TGTX) for 12,000 shares. The Connecticut-based Columbus Circle Invsts has invested 0.04% in TG Therapeutics Inc (NASDAQ:TGTX). Secor Capital Advsrs Ltd Partnership accumulated 0.02% or 30,820 shares. Schwab Charles Inv Management Inc last reported 59,050 shares in the company. State Street reported 624,307 shares or 0% of all its holdings. Moreover, Public Employees Retirement Association Of Colorado has 0% invested in TG Therapeutics Inc (NASDAQ:TGTX) for 13,349 shares. The New York-based New York State Common Retirement Fund has invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). Millennium Ltd Co has 198,298 shares for 0% of their US portfolio. Northern Tru holds 460,288 shares or 0% of its portfolio. Oxford Asset Mngmt, a United Kingdom-based fund reported 78,427 shares. Metropolitan Life Insurance Ny has 25,432 shares for 0% of their US portfolio. Susquehanna Group Incorporated Limited Liability Partnership last reported 30,023 shares in the company. California State Teachers Retirement Sys holds 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX) for 77,235 shares. Voya Limited Liability reported 14,870 shares or 0% of all its holdings. Blackrock Management Ltd Limited Liability Company last reported 0% of its portfolio in the stock.
Insider Transactions: Since April 18, 2016, the stock had 0 insider buys, and 2 insider sales for $403,252 net activity. $101,200 worth of TG Therapeutics Inc (NASDAQ:TGTX) shares were sold by Power Sean A.
Another recent and important TG Therapeutics Inc (NASDAQ:TGTX) news was published by Fool.com which published an article titled: “The Reason Behind TG Therapeutics Inc.’s Soaring Stock Price” on June 18, 2015.
TGTX Company Profile
TG Therapeutics, Inc. (TG), incorporated on May 18, 1993, is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Firm is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Firm is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Firm also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Firm also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.